Experiences with Ezetimibe or Empagliflozin?

Key Takeaways

• Most users report zero side effects at 10‑25 mg doses
• Empagliflozin flattens post‑meal glucose spikes, may cause mild diuresis
• Ezetimibe lowers LDL‑C to ~45 mg/dL, crosses blood‑brain barrier
• Retrospective study links ezetimibe to 8‑fold lower Alzheimer’s risk
• SGLT2 inhibitors can increase urinary‑tract infection risk in susceptible individuals

Pulse Analysis

The longevity community is increasingly experimenting with repurposed pharmaceuticals, and ezetimibe and empagliflozin have emerged as low‑cost candidates. Users typically dose ezetimibe at 10 mg daily and empagliflozin between 10 mg and 25 mg, reporting negligible adverse events. Empagliflozin’s primary benefit appears to be attenuation of post‑prandial glucose excursions, a factor that may support metabolic health without compromising exercise performance. The most common inconvenience is increased urinary frequency, especially in the hours following ingestion, prompting many to schedule the dose in the morning.

Beyond lipid‑lowering, ezetimibe is gaining attention for potential neuroprotective properties. A hypothesis‑neutral screen identified the drug as a disruptor of the 14‑3‑3/hexokinase interaction, a pathway implicated in protein misfolding in Alzheimer’s disease. In vitro studies showed reductions in amyloid and tau aggregates, while animal models confirmed similar effects. A retrospective analysis of over 4,300 ezetimibe users versus nearly one million controls reported an eight‑fold lower incidence of Alzheimer’s, independent of cardiovascular status. Although compelling, these findings lack randomized controlled trial validation, and confounding variables remain a concern.

If future trials substantiate the cognitive benefits and confirm the safety profile, ezetimibe could become a staple in preventive medicine, expanding its market beyond cholesterol management. Meanwhile, clinicians must weigh the modest risk of urinary‑tract infections associated with SGLT2 inhibitors, particularly in women with obesity or diabetes. As the evidence base evolves, the intersection of metabolic control, lipid reduction, and neuroprotection may redefine how physicians approach longevity and age‑related disease prevention.